AI-powered search

T-Cell-Rich Lymphoid Infiltrates ID'd After Pfizer COVID-19 Shot

Three types of infiltrates revealed on histologic examination including cutaneous T-cell lymphoid hyperplasia

By Dermsquared Editorial Team | July 20, 2022

Cutaneous T-cell-rich lymphoid infiltrates have been reported after Pfizer BioNTech COVID-19 vaccination, according to a research letter published online July 20 in JAMA Surgery .

Madeline J. Hooper, from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues conducted a retrospective case series, including six cases of T-cell-rich cutaneous lymphoid infiltrates shortly after severe acute respiratory syndrome coronavirus 2 vaccination.

The researchers identified three male and three female patients, with a median age of 47 years. One patient had multiple sclerosis and one had a history of psoriasis and transverse myelitis. All patients received the Pfizer/BioNTech vaccine. The median time from the first dose to development of lesions was 22 days. Vaccine-related constitutional symptoms were reported by two patients, while three reported lesional pruritus. Cutaneous eruptions were characterized by single or generalized papulonodules on the trunk and/or extremities (two and four patients, respectively). T-cell-predominant lymphoid infiltrates consistent with pityriasis lichenoides et varioliformis acuta, cutaneous T-cell lymphoid hyperplasia, and lymphomatoid papulosis type A were revealed in two patients each on histologic examination. The clinical course was indolent; after various therapies, resolution was reported. After an acute viral episode, four of the patients reported recrudescence.

"Our observations should raise awareness about low-grade cutaneous lymphoid reactions after COVID-19 vaccination," the authors write.

Two authors disclosed financial ties to Kyowa Kirin, and one received a grant from Elorac.

Abstract/Full Text (subscription or payment may be required)


The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved